NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

GKOS

Glaukos Corporation

Apr 21 • 11:19AM ET

87.83

Dollar change -2.43
Percentage change -2.69	%

Healthcare • Medical Devices • USA • NYSE

Peers: ALGN ZBH BSX EW ISRG MDT SYK COO BAX HOLX

| Held by: IJR VTI VB IWM VXF VBK IJT SPSM IWO IHI

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.81	Insider Own	3.71%	Shs Outstand	56.44M	Perf Week	-2.49%
Market Cap	5.01B	Forward P/E	-	EPS next Y	-0.07	Insider Trans	-2.00%	Shs Float	54.97M	Perf Month	-12.72%
Income	-146.37M	PEG	-	EPS next Q	-0.35	Inst Own	101.20%	Short Float	6.30%	Perf Quarter	-43.84%
Sales	383.48M	P/S	13.07	EPS this Y	47.36%	Inst Trans	4.19%	Short Ratio	3.66	Perf Half Y	-31.49%
Book/sh	13.59	P/B	6.46	EPS next Y	93.07%	ROA	-14.33%	Short Interest	3.46M	Perf Year	-9.35%
Cash/sh	5.59	P/C	15.72	EPS next 5Y	-	ROE	-23.83%	52W Range	77.91 - 163.71	Perf YTD	-41.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-16.82%	52W High	-46.35%	Beta	0.85
Dividend TTM	-	Quick Ratio	5.22	Sales past 5Y	10.99%	Gross Margin	75.48%	52W Low	12.73%	ATR (14)	6.12
Dividend Ex-Date	-	Current Ratio	5.99	EPS Y/Y TTM	-1.18%	Oper. Margin	-28.20%	RSI (14)	39.55	Volatility	4.59% 6.32%
Employees	995	Debt/Eq	0.14	Sales Y/Y TTM	21.85%	Profit Margin	-38.17%	Recom	1.38	Target Price	154.31
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	19.72%	Payout	-	Rel Volume	0.47	Prev Close	90.26
Sales Surprise	4.72%	EPS Surprise	-4.33%	Sales Q/Q	28.09%	Earnings	Apr 30 AMC	Avg Volume	945.94K	Price	87.83
SMA20	-6.83%	SMA50	-20.49%	SMA200	-31.94%	Trades		Volume	140,782	Change	-2.69%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-19-25	Upgrade	Mizuho	Neutral → Outperform	$140 → $200
Dec-11-24	Upgrade	Citigroup	Neutral → Buy	$132 → $162
Dec-06-24	Initiated	UBS	Buy	$182
Dec-02-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$120
Jul-10-24	Downgrade	Citigroup	Buy → Neutral	$132
May-06-24	Upgrade	Jefferies	Hold → Buy	$84 → $125
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight	$66 → $91
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight	$65
Nov-28-23	Initiated	Truist	Buy	$88
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$75 → $83
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight	$55 → $80
Dec-22-22	Initiated	Mizuho	Neutral	$48
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral	$48 → $42
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$57
Oct-14-22	Resumed	Stephens	Overweight	$69
Oct-04-22	Initiated	Needham	Buy	$66
Jul-12-22	Upgrade	Stifel	Hold → Buy	$40 → $60
Feb-03-22	Upgrade	William Blair	Mkt Perform → Outperform
Jan-19-22	Upgrade	Wells Fargo	Underweight → Equal Weight	$56
Jan-18-22	Upgrade	BTIG Research	Neutral → Buy	$61

Show Previous Ratings

Apr-16-25 07:00AM	Glaukos Announces the Release of its 2024 Sustainability Report (Business Wire) -6.05%
Apr-10-25 09:04AM	Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? (Zacks)
Apr-09-25 07:00AM	Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 (Business Wire) +13.71%
Apr-08-25 09:41AM	What Makes Glaukos Corporation (GKOS) a Compelling Stock? (Insider Monkey)
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
08:48AM	Loading…
Apr-06-25 08:48AM	Glaukos: Macro Environment And Limited Market Access Could Stunt Growth Plans (Seeking Alpha)
Apr-02-25 12:01AM	Lord Abbett Developing Growth Fund Q4 2024 Commentary (Seeking Alpha)
Apr-01-25 10:49AM	The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals (Zacks)
Mar-31-25 09:10AM	3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space (Zacks)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-27-25 11:15AM	Columbia Select Mid Cap Growth Fund Q4 2024 Commentary (SeekingAlpha)
Mar-26-25 11:10AM	Columbia Acorn Fund Q4 2024 Commentary (SeekingAlpha)
Mar-11-25 07:00AM	RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire: A Next-Generation Visual Field Solution (Business Wire)
Mar-04-25 11:52PM	Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts? (Insider Monkey)
Feb-24-25 07:00AM	Glaukos Announces FDA Acceptance of NDA Submission for Epioxa (Business Wire)
07:47PM	Loading…
Feb-21-25 07:47PM	Wingstop Stocks Dip Is an Opportunity, Analyst Says. Plus, Devon Energy, Cadence Design, and More. (Barrons.com) -20.01%
02:15AM	Glaukos Corp (GKOS) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Growth Amid ... (GuruFocus.com)
Feb-20-25 05:40PM	Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:34PM	Glaukos: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
12:00PM	Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz (TipRanks)
08:54AM	What To Expect From Glaukos Corp (GKOS) Q4 2024 Earnings (GuruFocus.com)
Feb-17-25 09:16AM	What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings (Zacks)
Jan-23-25 07:00AM	Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20 (Business Wire)
Jan-14-25 04:05PM	Glaukos Announces Positive Clinical Updates for its iDose Sustained-Release Procedural Pharmaceutical Platform (Business Wire)
Jan-04-25 07:45AM	Glaukos price target raised to $157 from $149 at BTIG (TipRanks)
Dec-23-24 07:00AM	Glaukos Submits New Drug Application to U.S. FDA for Epioxa (Business Wire)
Dec-19-24 07:30AM	Glaukos price target raised to $185 from $152 at Truist (TipRanks)
Dec-17-24 07:00AM	Glaukos Announces Participation in the J.P. Morgan Healthcare Conference (Business Wire)
Dec-07-24 05:35AM	Glaukos initiated with a Buy at UBS (TipRanks)
02:29PM	Loading…
Dec-02-24 02:29PM	Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos (Benzinga)
Nov-08-24 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
Nov-06-24 06:30AM	Glaukos price target raised to $145 from $135 at Wells Fargo (TipRanks) +10.00%
Nov-05-24 11:30AM	Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
11:18AM	Q3 2024 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
02:08AM	Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sales and Raised Guidance Amid ... (GuruFocus.com)
Nov-04-24 05:25PM	Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Glaukos: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Third Quarter 2024 Financial Results (Business Wire)
Nov-01-24 09:01AM	Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result (GuruFocus.com)
Oct-28-24 10:01AM	Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-17-24 10:06AM	Glaukos eyes FDA approval for ocular therapy after Phase III win (Pharmaceutical Technology)
Oct-16-24 04:05PM	Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety (Business Wire)
Oct-14-24 07:00AM	Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting (Business Wire)
Oct-09-24 07:00AM	Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 (Business Wire)
Sep-09-24 05:16AM	Heres Why Glaukos (GKOS) Appreciated in Q2 (Insider Monkey)
Sep-03-24 02:16AM	Better Than Expected Earnings Results Boosted Glaukos Corp (GKOS) in Q2 (Insider Monkey)
Aug-22-24 01:16PM	Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock? (Zacks)
Aug-16-24 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
Aug-02-24 07:00PM	Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:50AM	Should You Be Bullish on Glaukos Corporation (GKOS)? (Insider Monkey)
Aug-01-24 11:40AM	Q2 2024 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
07:31AM	Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales (Zacks)
Jul-31-24 09:57PM	GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
06:20PM	Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:16PM	Glaukos: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Second Quarter 2024 Financial Results (Business Wire)
Jul-24-24 10:01AM	Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-22-24 11:27AM	Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock? (Zacks)
Jul-10-24 07:00AM	Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31 (Business Wire)
Jul-03-24 07:38AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Jun-27-24 12:49PM	Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock? (Zacks)
03:19AM	Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar? (Zacks)
Jun-14-24 07:00AM	Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock (Business Wire)
Jun-05-24 12:14PM	Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally? (Zacks)
Jun-03-24 01:53PM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
May-28-24 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
May-14-24 04:47PM	Glaukos Insider Sold Shares Worth $264,791, According to a Recent SEC Filing (MT Newswires)
12:20PM	Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock? (Zacks)
May-02-24 12:01PM	Needham Adjusts Price Target on Glaukos to $113 From $108, Maintains Buy Rating (MT Newswires) +6.19%
11:59AM	JPMorgan Adjusts Price Target on Glaukos to $110 From $108, Maintains Overweight Rating (MT Newswires)
09:14AM	Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y (Zacks)
07:12AM	Q1 2024 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
03:38AM	Glaukos Corp (GKOS) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ... (GuruFocus.com)
May-01-24 11:53PM	GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:50PM	Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:35PM	Glaukos Corp (GKOS) Q1 2024 Earnings: Misses Analyst EPS Forecast, Surpasses Revenue Expectations (GuruFocus.com)
04:50PM	Glaukos: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces First Quarter 2024 Financial Results (Business Wire)
Apr-16-24 04:05PM	Glaukos Announces the Release of its 2023 Sustainability Report (Business Wire)
Apr-15-24 08:19AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Apr-12-24 09:22AM	Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally? (Zacks)
Apr-10-24 07:00AM	Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1 (Business Wire)
Apr-08-24 10:41AM	Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock? (Zacks)
Apr-04-24 12:02PM	Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS (Zacks)
Apr-03-24 07:00AM	Glaukos Receives Permanent J-code for iDose TR (travoprost intracameral implant) (Business Wire) +5.40%
Apr-01-24 07:00AM	Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting (Business Wire)
Mar-22-24 11:30AM	Glaukos (GKOS) Down 4.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-13-24 07:56AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Feb-27-24 02:03AM	Glaukos Corp Director Mark Foley Sells 4,560 Shares (GuruFocus.com)
Feb-22-24 10:16AM	Glaukos Corporation (NYSE:GKOS) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:58AM	Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks)
07:47AM	Q4 2023 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-21-24 05:20PM	Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:35PM	Glaukos Corp (GKOS) Reports Increased Sales but Widening Losses in Q4 and Full Year 2023 (GuruFocus.com)
04:17PM	Glaukos: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-15-24 02:04AM	Insider Sell: Glaukos Corp's President & COO Joseph Gilliam Sells 1,512 Shares (GuruFocus.com)
Feb-14-24 10:00AM	Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:15AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Mar 25 '25	Sale	106.84	1,520	162,399	53,431	Mar 27 07:14 PM
Thurman Alex R.	Officer	Mar 25 '25	Proposed Sale	106.84	1,520	162,402		Mar 25 04:23 PM
Foley Mark J	Director	Feb 26 '25	Option Exercise	29.26	40,000	1,170,350	74,936	Feb 28 05:57 PM
Foley Mark J	Director	Feb 26 '25	Sale	120.72	20,687	2,497,335	54,249	Feb 28 05:57 PM
Foley Mark J	Director	Feb 26 '25	Proposed Sale	120.72	20,687	2,497,263		Feb 26 03:57 PM
Navratil Tomas	CHIEF DEVELOPMENT OFFICER	Feb 14 '25	Sale	147.14	3,416	502,630	72,437	Feb 19 06:00 PM
Navratil Tomas	Officer	Feb 14 '25	Proposed Sale	147.14	3,416	502,630		Feb 14 10:13 AM
Gilliam Joseph E	PRESIDENT & COO	Dec 20 '24	Option Exercise	59.74	3,328	198,830	105,497	Dec 23 09:15 PM
Gilliam Joseph E	PRESIDENT & COO	Dec 20 '24	Sale	149.85	3,328	498,716	102,169	Dec 23 09:15 PM
Kliman Gilbert H	Director	Dec 20 '24	Option Exercise	32.00	10,000	320,000	42,336	Dec 23 07:53 PM
Kliman Gilbert H	Director	Dec 20 '24	Sale	150.28	10,000	1,502,800	32,336	Dec 23 07:53 PM
Gilliam Joseph E	Officer	Dec 20 '24	Proposed Sale	149.85	3,657	548,017		Dec 20 04:27 PM
Kliman Gilbert H	Director	Dec 20 '24	Proposed Sale	150.28	10,000	1,502,789		Dec 20 04:21 PM
Kliman Gilbert H	Director	Dec 11 '24	Option Exercise	32.00	2,000	64,000	34,336	Dec 13 07:50 PM
Kliman Gilbert H	Director	Dec 11 '24	Sale	144.01	2,000	288,020	32,336	Dec 13 07:50 PM
Kliman Gilbert H	Director	Dec 11 '24	Proposed Sale	144.01	2,000	288,015		Dec 11 12:32 PM
Gilliam Joseph E	PRESIDENT & COO	Oct 30 '24	Option Exercise	69.30	2,275	157,658	104,444	Nov 01 05:30 PM
Gilliam Joseph E	PRESIDENT & COO	Oct 30 '24	Sale	138.97	2,275	316,157	102,169	Nov 01 05:30 PM
Gilliam Joseph E	Officer	Oct 30 '24	Proposed Sale	138.97	2,500	347,421		Oct 30 04:18 PM
Kliman Gilbert H	Director	Sep 09 '24	Option Exercise	32.00	3,000	96,000	35,336	Sep 11 07:49 PM
Kliman Gilbert H	Director	Sep 09 '24	Sale	130.67	3,000	392,000	32,336	Sep 11 07:49 PM
Kliman Gilbert H	Director	Sep 09 '24	Proposed Sale	130.67	3,000	392,000		Sep 09 03:03 PM
Gilliam Joseph E	PRESIDENT & COO	Aug 21 '24	Option Exercise	55.18	5,000	275,900	107,169	Aug 23 05:25 PM
Gilliam Joseph E	PRESIDENT & COO	Aug 21 '24	Sale	129.36	5,000	646,791	102,169	Aug 23 05:25 PM
Gilliam Joseph E	Officer	Aug 21 '24	Proposed Sale	129.36	5,000	646,803		Aug 21 04:19 PM
Stapley Marc	Director	Aug 15 '24	Option Exercise	32.00	6,250	200,000	40,326	Aug 19 05:15 PM
Stapley Marc	Director	Aug 15 '24	Sale	125.93	6,250	787,086	34,076	Aug 19 05:15 PM
Stapley Marc	Director	Aug 15 '24	Proposed Sale	125.93	6,250	787,074		Aug 15 05:12 PM
WEISNER AIMEE S	Director	Aug 08 '24	Option Exercise	32.00	25,000	800,000	55,119	Aug 12 05:05 PM
WEISNER AIMEE S	Director	Aug 08 '24	Sale	120.00	25,000	3,000,000	30,119	Aug 12 05:05 PM
WEISNER AIMEE S	Director	Aug 08 '24	Proposed Sale	120.00	25,000	3,000,000		Aug 08 12:15 PM
Gilliam Joseph E	PRESIDENT & COO	Jul 05 '24	Option Exercise	69.30	2,250	155,925	104,095	Jul 09 05:10 PM
Gilliam Joseph E	PRESIDENT & COO	Jul 05 '24	Sale	121.39	2,250	273,128	101,845	Jul 09 05:10 PM
Gilliam Joseph E	PRESIDENT & COO	Jun 03 '24	Option Exercise	55.18	2,500	137,950	104,345	Jun 05 07:35 PM
Gilliam Joseph E	PRESIDENT & COO	Jun 03 '24	Sale	113.50	2,500	283,751	101,845	Jun 05 07:35 PM
Kliman Gilbert H	Director	May 30 '24	Option Exercise	32.00	5,000	160,000	35,620	Jun 03 09:00 PM
Kliman Gilbert H	Director	May 30 '24	Sale	112.00	5,000	560,000	30,620	Jun 03 09:00 PM
Stapley Marc	Director	May 15 '24	Option Exercise	32.00	6,250	200,000	38,610	May 16 07:45 PM
Stapley Marc	Director	May 15 '24	Sale	112.80	6,250	704,993	32,360	May 16 07:45 PM
Gilliam Joseph E	PRESIDENT & COO	May 10 '24	Option Exercise	55.18	2,395	132,156	104,240	May 14 04:43 PM
Gilliam Joseph E	PRESIDENT & COO	May 10 '24	Sale	110.56	2,395	264,791	101,845	May 14 04:43 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	May 10 '24	Sale	110.51	353	39,011	51,647	May 14 04:41 PM
Gilliam Joseph E	PRESIDENT & COO	May 06 '24	Option Exercise	55.18	105	5,794	101,950	May 08 05:21 PM
Gilliam Joseph E	PRESIDENT & COO	May 06 '24	Sale	110.36	105	11,588	101,845	May 08 05:21 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	May 06 '24	Sale	110.26	90	9,923	52,000	May 08 05:08 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	May 02 '24	Sale	105.69	442	46,713	52,090	May 06 05:27 PM
Gilliam Joseph E	PRESIDENT & COO	May 02 '24	Option Exercise	69.30	2,059	142,689	103,904	May 06 05:23 PM
Gilliam Joseph E	PRESIDENT & COO	May 02 '24	Sale	105.52	2,059	217,263	101,845	May 06 05:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GKOS

Glaukos Corporation

Upgrade your FINVIZ experience